| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
2e-06 |
| mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
9e-06 |
| mRNA |
Genentech Cpd 10 |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
3e-05 |
| mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
3e-05 |
| mRNA |
ceranib-2 |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
5e-05 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
5e-05 |
| mRNA |
Compound 7d-cis |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
7e-05 |
| mRNA |
GSK1070916 |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
8e-05 |
| mRNA |
selumetinib:PLX-4032 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0001 |
| mRNA |
LY-2183240 |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0002 |